Dr Jim Philips - Non-Executive Chairman

Jim has over 21 years' healthcare industry experience, and is a qualified physician with an MBA from Cass Business School. Jim worked for Johnson & Johnson and Novartis in senior executive roles, and was founder and Chief Executive Officer of Talisker Pharmaceuticals Ltd, which was acquired by EUSA Pharma Inc in July 2006 giving investors a successful exit. Jim also took Bone Medical Ltd through its oversubscribed IPO in Australia in 2004 (as Chief Executive). Jim has held a number of other international board level roles including with organizations such as West Sussex Health Authority, Lifeguard Technologies Ltd, CRF Inc, Diabetology Ltd, EUSA Pharma Inc, and OPi S.A. Jim has extensive experience in clinical, business development, and commercialisation in pharmaceuticals, and also in leading the development of early stage ventures.

David Hipkiss - CEO and Co-Founder

David is a co-founder of Prosonix and has led the Company as CEO since its establishment, enjoying sustained and dramatic business growth throughout the period and leading the successful £11.4M Series B funding round in June 2011 and a £5M Series A round in November 2007. Prior to Prosonix, he was General Manager of the C³ Technology Business of Accentus, which he established after joining them as Global Licensing Director in 2002. He has nearly 20 years' experience in business development and international marketing of cutting edge technologies in high growth, complex, intellectual property-rich environments, with a prime focus in the pharmaceutical industry. He has also held a number of senior positions with international responsibility in Dow Chemicals, Ascot plc, ChiroTech, and Air Products and Chemicals Inc. David holds a Bachelors' Degree in Chemical Engineering.

Andy Bush - COO/CFO and Co-Founder

Andy is a co-founder of Prosonix and, as COO/CFO, has managed the establishment, development and profitable growth of the business since formation in 2006 to deliver key strategic elements of the business plan. Andy has nearly 25 years' experience in international business management, including both operational capability development and financial control, while supporting major commercial deal making. Prior to joining Prosonix, he was Operations Manager of the C³ Technology Business of Accentus and previously held senior positions in two AEA Technology businesses in change management and business transformation roles. Before that he enjoyed a highly successful 18 year career in BOC spanning technical, operations and commercial management and was responsible for winning several long-term, multi-million pound business contracts. Andy holds a Bachelors' Degree in Chemical Engineering, and is a Chartered Engineer. He also holds a Masters' Degree in Business Administration.

Ken Cunningham - Non-Executive Director

Ken Cunningham joined Prosonix as a Non-executive Director in August 2011 and is the Chair of the Advisory Board. Ken has over 20 years' experience in the pharmaceutical industry. He is Executive Chairman of PolyTherics Ltd and until August 2010 was CEO of Skyepharma plc. Before that he was Chief Executive Officer of Arakis Ltd, Vice-President European Affairs at Alza Corporation and Vice-President Clinical Development at Sequus Inc. Prior to this he held a variety of clinical development and commercial strategy roles at GlaxoWellcome plc and Warner-Lambert earlier in his career. Ken is also a Non-Executive Director of Xention Ltd. He holds a medical degree from St Mary's, Imperial College, London University.

Laurent Assaraf - Non-Executive Director

Laurent joined Ventech in 2002 and is Principal in the Life Sciences sector. He sits on the board of Graftys, Eyegate Pharmaceuticals, Themis, Prosonix, and ActoGenix. Before joining Ventech, Laurent was a financial analyst at Oddo Securities, a leading French broker. He was working on the analysis of pharmaceutical product portfolio well as on the assessment of their potential. Laurent holds a Pharm-D and a MBA from IAE, Paris.

Edwin De Graaf - Non-Executive Director

Edwin is a Senior Partner at Gilde Investment Management, which he joined in 1997. He became investment manager of Gilde Strategic Situations Fund - a fund of funds - and was involved with investments in funds managed by AXA (France), Amadeus (UK), Technologie Holding (now 3i, Germany) and OneLiberty Ventures (now Flagship Ventures, US). In 1998 he was appointed investment manager and later investment director of Gilde Healthcare I. Edwin received EVCJ's "Venture Realization of the Year - Life Science award" in 2005 for the trade of GlycArt to Roche. Previously, he served for three years as a tax consultant in the International Tax department of Coopers & Lybrand in the Netherlands, specializing in Value Added Tax. Edwin holds a Masters' Degree in Business and Fiscal Economics from the Erasmus University in Rotterdam.

Klaas de Boer - Non-Executive Director

Klaas is the Managing Partner of the Entrepreneurs Fund. He joined the fund in 2006. Klaas previously created and led a corporate venturing team at Vanenburg Group whose investments included WebEx. Following this, he spent time as a consultant with McKinsey and Company in both Amsterdam and St Petersburg. Behind Klaas' achievements are an MSc in Physics and an MBA from Insead.

Andrew is a Partner in Nova Capital Management. He has over 25 years of general management experience in engineering, marketing and business development at an international level. Prior to joining Nova in 2003, Andrew was a Project Director at Gulf Oil International and subsequently spent seven years with Texaco, joining as a Divisional Managing Director. In both businesses, Andrew was responsible for executing major start-up projects. Andrew has a Bachelor's Degree in Engineering, is a chartered engineer and holds a Master's Degree in International Marketing.